NASDAQ:GRAY - Graybug Vision Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $17.29
  • Forecasted Upside: 333.23 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.99
▲ +0.03 (0.76%)

This chart shows the closing price for GRAY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Graybug Vision Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRAY

Analyst Price Target is $17.29
▲ +333.23% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Graybug Vision in the last 3 months. The average price target is $17.29, with a high forecast of $41.00 and a low forecast of $4.00. The average price target represents a 333.23% upside from the last price of $3.99.

This chart shows the closing price for GRAY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 polled investment analysts is to hold stock in Graybug Vision.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/10/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
11/8/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/7/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/6/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
8/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/19/2021Needham & Company LLCReiterated RatingBuy ➝ HoldLow
5/18/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$23.00 ➝ $5.00Low
5/13/2021Cantor FitzgeraldLower Price TargetOverweight$14.00 ➝ $6.00High
5/13/2021Needham & Company LLCDowngradeBuy ➝ HoldHigh
5/12/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$23.00 ➝ $5.00High
5/12/2021Piper SandlerLower Price TargetNeutral$10.00 ➝ $4.00High
3/15/2021Piper SandlerReiterated RatingOverweight ➝ Neutral$27.00 ➝ $10.00N/A
3/15/2021WedbushReiterated RatingOutperform ➝ Neutral$41.00 ➝ $8.00N/A
3/9/2021WedbushDowngradeOutperform ➝ Neutral$41.00 ➝ $8.00Medium
3/9/2021SVB LeerinkLower Price TargetOutperform$45.00 ➝ $23.00High
3/9/2021Piper SandlerDowngradeOverweight ➝ Neutral$27.00 ➝ $10.00High
12/21/2020Cantor FitzgeraldInitiated CoverageOverweight$42.00High
10/20/2020OppenheimerInitiated CoverageOutperform$41.00Low
10/20/2020Robert W. BairdInitiated CoverageOverweight$27.00High
10/20/2020SVB LeerinkInitiated CoverageOutperform$35.00High
10/20/2020WedbushInitiated CoverageOutperform$41.00High
10/20/2020Piper SandlerInitiated CoverageOverweight$27.00High
10/20/2020Needham & Company LLCInitiated CoverageBuy$30.00High
(Data available from 8/5/2016 forward)
Graybug Vision logo
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Read More

Today's Range

Now: $3.99
Low: $3.92
High: $4.05

50 Day Range

MA: $4.63
Low: $3.85
High: $6.10

52 Week Range

Now: $3.99
Low: $3.43
High: $37.88

Volume

115,660 shs

Average Volume

320,366 shs

Market Capitalization

$84.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Graybug Vision?

The following Wall Street sell-side analysts have issued research reports on Graybug Vision in the last twelve months: Cantor Fitzgerald, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for GRAY.

What is the current price target for Graybug Vision?

7 Wall Street analysts have set twelve-month price targets for Graybug Vision in the last year. Their average twelve-month price target is $17.29, suggesting a possible upside of 333.2%. Oppenheimer Holdings Inc. has the highest price target set, predicting GRAY will reach $41.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $4.00 for Graybug Vision in the next year.
View the latest price targets for GRAY.

What is the current consensus analyst rating for Graybug Vision?

Graybug Vision currently has 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GRAY, but not buy more shares or sell existing shares.
View the latest ratings for GRAY.

What other companies compete with Graybug Vision?

How do I contact Graybug Vision's investor relations team?

The company's listed phone number is 650-487-2800 and its investor relations email address is [email protected] The official website for Graybug Vision is www.graybug.com.